PD-L1 is Fascinating but IDO Needs Attention in Non-HCV and Non-HBV-Associated Hepatocellular Carcinoma Patients

Overview

Journal J Hepatocell Carcinoma

Date 2023 Jun 23

PMID 37350801

Authors

Kashif Asghar

Shaarif Bashir

Iftikhar Ali Rana

Muhammad Abu Bakar

Asim Farooq

Muhammad Hassan

Zukhruf Asif

Mahnoor Afzal

Iqra Masood

Muhammad Ishaq

Muhammad Tahseen

Sundus Bilal

Shafqat Mehmood

Nosheen Kanwal

Islah Ud Din

Asif Loya

Affiliations

Soon will be listed here.

Abstract

Background/aim: Hepatocellular carcinoma (HCC) is one of the most common forms of liver cancer that is modulated by the immune system. Programmed cell death ligand-1 (PD-L1) has emerged as a novel therapeutic target in various cancers. Indoleamine 2,3-dioxygenase (IDO) is an immunosuppressive enzyme that is associated with poor prognoses in various cancer types. The aim of this study was to investigate the PD-L1 expression, and clinicopathological features of non-HCV and non-HBV-associated HCC patients, including IDO expression.

Patients And Methods: In this study, immunohistochemical analysis was performed to analyze the expression of PD-L1 and IDO. Formalin-fixed paraffin-embedded HCC tumor tissues (n=50) were obtained from the pathology department, at Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC) in Lahore, Pakistan between 2005 and 2022. All the patients were HBV and HCV negative. Furthermore, it was a rare group of patients with no previous history of any viral hepatitis. In addition, for categorical and continuous variables chi-square or Fisher exact test and Mann-Whitney -test was performed.

Results: Of 50 tissue specimens, PD-L1+ was observed in 21 [high: 12 (24%), low: 9 (18%)] and PD-L1- was observed in 29 HCC patients. IDO+ was observed in all 50 specimens [high: 42 (84%), low: 8 (16%)]. Additionally, both PD-L1 and IDO had high expression in 11 (22%) patients. While both PD-L1 and IDO had low expression in 2 (4%) patients. Furthermore, in IDO+/PD-L1- group, 20 (69%) out of 29 patients died while in the IDO+/PD-L1+ group, 9 (43%) out of 21 patients died.

Conclusion: Evaluation of IDO and PD-L1 expression may add therapeutic advantage in non-HCV and non-HBV-associated HCC patients that overexpress IDO. Further validation in a larger cohort is warranted.

References

Liu H, Shen Z, Wang Z, Wang X, Zhang H, Qin J . Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma. Sci Rep. 2016; 6:21319. PMC: 4758033. DOI: 10.1038/srep21319. View

Yin X, Wu T, Lan Y, Yang W . Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma. Biosci Rep. 2022; 42(2). PMC: 8821949. DOI: 10.1042/BSR20212304. View

Tateishi R, Okanoue T, Fujiwara N, Okita K, Kiyosawa K, Omata M . Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. J Gastroenterol. 2014; 50(3):350-60. PMC: 4352653. DOI: 10.1007/s00535-014-0973-8. View

Patel S, Kurzrock R . PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015; 14(4):847-56. DOI: 10.1158/1535-7163.MCT-14-0983. View

Liang F, Wang G, Wang Y, Yang Y, Wen Z, Chen D . Tobacco carcinogen induces tryptophan metabolism and immune suppression via induction of indoleamine 2,3-dioxygenase 1. Signal Transduct Target Ther. 2022; 7(1):311. PMC: 9448807. DOI: 10.1038/s41392-022-01127-3. View

Nagaoki Y, Hyogo H, Ando Y, Kosaka Y, Uchikawa S, Nishida Y . Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study. BMC Gastroenterol. 2021; 21(1):306. PMC: 8325833. DOI: 10.1186/s12876-021-01884-5. View

Asghar K, Farooq A, Zulfiqar B, Rashid M . Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma. World J Gastroenterol. 2017; 23(13):2286-2293. PMC: 5385395. DOI: 10.3748/wjg.v23.i13.2286. View

Asghar K, Brain J, Palmer J, Douglass S, Naemi F, OBoyle G . Potential role of indoleamine 2,3-dioxygenase in primary biliary cirrhosis. Oncol Lett. 2017; 14(5):5497-5504. PMC: 5652243. DOI: 10.3892/ol.2017.6834. View

Li X, Wang X, Gao P . Diabetes Mellitus and Risk of Hepatocellular Carcinoma. Biomed Res Int. 2018; 2017:5202684. PMC: 5742888. DOI: 10.1155/2017/5202684. View

10.

Brown Z, Yu S, Heinrich B, Ma C, Fu Q, Sandhu M . Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma. Cancer Immunol Immunother. 2018; 67(8):1305-1315. PMC: 6085109. DOI: 10.1007/s00262-018-2190-4. View

11.

Paterson A, Brown K, Keir M, Vanguri V, Riella L, Chandraker A . The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol. 2011; 187(3):1097-105. PMC: 3148082. DOI: 10.4049/jimmunol.1003496. View

12.

van Doorn D, Takkenberg R, Klumpen H . Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview. Pharmaceuticals (Basel). 2020; 14(1). PMC: 7821931. DOI: 10.3390/ph14010003. View

13.

Ambade A, Mandrekar P . Oxidative stress and inflammation: essential partners in alcoholic liver disease. Int J Hepatol. 2012; 2012:853175. PMC: 3303590. DOI: 10.1155/2012/853175. View

14.

Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu M, Allen C . The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017; 3(12):1683-1691. PMC: 5824275. DOI: 10.1001/jamaoncol.2017.3055. View

15.

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

16.

Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y . Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res. 2005; 11(16):6030-9. DOI: 10.1158/1078-0432.CCR-04-2671. View

17.

Cooper W, Tran T, Vilain R, Madore J, Selinger C, Kohonen-Corish M . PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer. 2015; 89(2):181-8. DOI: 10.1016/j.lungcan.2015.05.007. View

18.

Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S . Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother. 2006; 56(8):1173-82. PMC: 11029839. DOI: 10.1007/s00262-006-0266-z. View

19.

Gao Q, Wang X, Qiu S, Yamato I, Sho M, Nakajima Y . Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009; 15(3):971-9. DOI: 10.1158/1078-0432.CCR-08-1608. View

20.

Wei R, Guo L, Wang Q, Miao J, Kwok H, Lin Y . Targeting PD-L1 Protein: Translation, Modification and Transport. Curr Protein Pept Sci. 2018; 20(1):82-91. DOI: 10.2174/1389203719666180928105632. View